billHR1492•Event Friday, February 21, 2025Analyzed

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Bullish

Impact5/10

Pfizer ($PFE)Merck ($MRK)Bristol-Myers Squibb ($BMY)Eli Lilly ($LLY)Amgen ($AMGN)Gilead Sciences ($GILD)Vertex Pharmaceuticals ($VRTX)Healthcare

Summary

HR1492, if enacted, would extend the negotiation period for small-molecule drugs under Medicare's Drug Price Negotiation Program from 7 to 11 years, aligning it with biologics. This change retroactively protects pharmaceutical companies' revenue streams from small-molecule drugs for an additional four years, directly benefiting major pharmaceutical manufacturers. The bill is currently in the early stages, having been referred to two committees.

Key Takeaways

1.HR1492 extends the negotiation period for small-molecule drugs under Medicare's Drug Price Negotiation Program from 7 to 11 years, aligning with biologics.
2.The change is retroactive, benefiting pharmaceutical companies by delaying price negotiations and preserving revenue streams for an additional four years.
3.The bill is in early legislative stages, having been referred to two House committees, indicating a lengthy path to potential enactment.

Market Implications

The potential enactment of HR1492 presents a bullish structural catalyst for pharmaceutical companies with significant small-molecule drug portfolios. By extending market exclusivity before price negotiations, companies like Pfizer ($PFE), Merck & Co. ($MRK), Bristol-Myers Squibb ($BMY), Eli Lilly and Company ($LLY), Amgen Inc. ($AMGN), Gilead Sciences ($GILD), and Vertex Pharmaceuticals ($VRTX) could see enhanced long-term revenue visibility for their small-molecule products. While recent market data shows varied short-term performance across these tickers, the legislative intent of HR1492, if passed, would be a positive development for their future earnings potential by mitigating a significant regulatory headwind. For example, Merck ($MRK) has seen a 30-day gain of 2.15% while others like Eli Lilly ($LLY) and Amgen ($AMGN) have experienced declines of 7.35% and 8.44% respectively over the same period, suggesting current market movements are not directly tied to this early-stage bill.

Full Analysis

HR1492 was introduced in the House on February 21, 2025, and subsequently referred to the Committee on Energy and Commerce and the Committee on Ways and Means. The bill aims to amend Section 1192(e)(1)(A)(ii) of the Social Security Act to change the market approval requirement for small-molecule drugs to qualify for negotiation under the Medicare Drug Price Negotiation Program from 7 years to 11 years, matching the period for biologics. This change would apply retroactively, effectively extending the period before small-molecule drugs become subject to price negotiation. This bill does not involve direct funding authorization or appropriation. Instead, it modifies a regulatory framework that impacts the revenue potential of pharmaceutical products. By extending the negotiation-free period for small-molecule drugs, the bill provides an additional four years of market exclusivity at potentially higher prices for these drugs. This regulatory relief directly benefits pharmaceutical companies that develop and market small-molecule drugs, as it delays the onset of government-mandated price negotiations, thereby preserving revenue streams for a longer duration. Structural winners include major pharmaceutical companies with significant small-molecule drug portfolios. Companies like Pfizer ($PFE), Merck & Co. ($MRK), Bristol-Myers Squibb ($BMY), Eli Lilly and Company ($LLY), Amgen Inc. ($AMGN), Gilead Sciences ($GILD), and Vertex Pharmaceuticals ($VRTX) are positioned to benefit from this extended protection. The bill's retroactive application means that drugs already on the market that would have been subject to negotiation under the 7-year rule could receive an additional four years of protection. Conversely, Medicare and its beneficiaries would face higher drug costs for these small-molecule drugs for an extended period. Recent market data shows mixed performance for these pharmaceutical companies. Over the past 7 days, Pfizer ($PFE) is down 3.7%, Merck ($MRK) is down 1.67%, Bristol-Myers Squibb ($BMY) is down 3.79%, Eli Lilly ($LLY) is down 0.24%, Amgen ($AMGN) is down 3.84%, Gilead Sciences ($GILD) is down 0.26%, and Vertex Pharmaceuticals ($VRTX) is down 4.37%. Over the past 30 days, Pfizer ($PFE) is down 0.04%, Merck ($MRK) is up 2.15%, Bristol-Myers Squibb ($BMY) is down 3.22%, Eli Lilly ($LLY) is down 7.35%, Amgen ($AMGN) is down 8.44%, Gilead Sciences ($GILD) is down 3.42%, and Vertex Pharmaceuticals ($VRTX) is down 6.5%. The bill is in its early stages, having been referred to two committees, indicating that significant legislative steps, including committee hearings, markups, and votes in both chambers, remain before it could become law.